1. Modifying the minimum criteria for diagnosing amnestic MCI to improve prediction of brain atrophy and progression to Alzheimer’s disease
- Author
-
William S. Kremen, Dominic Holland, Eero Vuoksimaa, Linda K. McEvoy, Carol E. Franz, Cognitive and Brain Aging, Institute for Molecular Medicine Finland, and University of Helsinki
- Subjects
NATIONAL INSTITUTE ,SEGMENTATION ,Hippocampus ,Audiology ,Neuropsychological Tests ,3124 Neurology and psychiatry ,RECOMMENDATIONS ,Behavioral Neuroscience ,0302 clinical medicine ,MARKERS ,Episodic memory ,Neuroradiology ,Original Research ,05 social sciences ,VERBAL-LEARNING TEST ,Neuropsychology ,Neuropsychological testing ,Early detection ,Alzheimer's disease ,Magnetic Resonance Imaging ,Psychiatry and Mental health ,Neurology ,Disease Progression ,ASSOCIATION WORKGROUPS ,Alzheimer’s disease ,medicine.medical_specialty ,Cognitive Neuroscience ,SURFACE-BASED ANALYSIS ,050105 experimental psychology ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,Atrophy ,Neuroimaging ,Alzheimer Disease ,medicine ,Humans ,0501 psychology and cognitive sciences ,Radiology, Nuclear Medicine and imaging ,Cognitive Dysfunction ,business.industry ,3112 Neurosciences ,Mild cognitive impairment ,medicine.disease ,Entorhinal cortex ,HYPOTHETICAL MODEL ,Free recall ,Neurology (clinical) ,business ,030217 neurology & neurosurgery ,Biomarkers - Abstract
Mild cognitive impairment (MCI) is a heterogeneous condition with variable outcomes. Improving diagnosis to increase the likelihood that MCI reliably reflects prodromal Alzheimer’s Disease (AD) would be of great benefit for clinical practice and intervention trials. In 230 cognitively normal (CN) and 394 MCI individuals from the Alzheimer’s Disease Neuroimaging Initiative, we studied whether an MCI diagnostic requirement of impairment on at least two episodic memory tests improves 3-year prediction of medial temporal lobe atrophy and progression to AD. Based on external age-adjusted norms for delayed free recall on the Rey Auditory Verbal Learning Test (AVLT), MCI participants were further classified as having normal (AVLT+, above −1 SD, n = 121) or impaired (AVLT -, −1 SD or below, n = 273) AVLT performance. CN, AVLT+, and AVLT- groups differed significantly on baseline brain (hippocampus, entorhinal cortex) and cerebrospinal fluid (amyloid, tau, p-tau) biomarkers, with the AVLT- group being most abnormal. The AVLT- group had significantly more medial temporal atrophy and a substantially higher AD progression rate than the AVLT+ group (51% vs. 16%, p
- Published
- 2018